Structure Therapeutics CEO discusses oral GLP-1 strategy, Phase 3 plans, and why pills and combination therapies may reshape ...

Viking CEO Brian Lian said at the conference earlier this week that the strategic interest in weight-loss drug deals is ...

Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its ...

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best up and coming stocks to buy according to Wall Street. On December 19, H.C. Wainwright analyst Ananda Ghosh raised the firm’s price target ...

The collaboration will leverage Abalone Bio’s Functional Antibody Selection Technology platform for an undisclosed ...

Structure Therapeutics (GPCR) has been in focus after reporting positive phase 2 results for its oral weight loss candidate ...

Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies -- Kainova Therapeutics rebrand reflects expanding capabilities powering next stage of ...

Investors in Structure Therapeutics Inc (Symbol: GPCR) saw new options begin trading today, for the December 2026 expiration. One of the key data points that goes into the price an option buyer is ...

As of Tuesday, January 13, Structure Therapeutics Inc.’s GPCR share price has surged by 6.29%, which has investors ...